Effect of levamisol on cellular and humoral immune reactivity and on recurrences in patients with bladder papilloma

I. Romics, J. Horváth, J. Fehér, A. Csontai

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Ten patients who had undergone repeated surgical interventions for bladder papilloma with successive recurrences within intervals of a few months, were given levamisol in weekly doses of 300 mg over a year, and were followed up for various cellular immune reactions, as well as for serum globulin and for acute-phase protein concentrations in the course of treatment. Levamisol was found to act primarily on cell-borne responsiveness. The recurrence-free intervals increased in the course of treatment. Four patients have remained free from recurrences since the start of treatment.

Original languageEnglish
Pages (from-to)323-330
Number of pages8
JournalInternational Urology and Nephrology
Volume17
Issue number4
DOIs
Publication statusPublished - Dec 1985

Fingerprint

Papilloma
Urinary Bladder
Recurrence
Serum Globulins
Acute-Phase Proteins
Therapeutics

ASJC Scopus subject areas

  • Urology
  • Nephrology
  • Geriatrics and Gerontology

Cite this

Effect of levamisol on cellular and humoral immune reactivity and on recurrences in patients with bladder papilloma. / Romics, I.; Horváth, J.; Fehér, J.; Csontai, A.

In: International Urology and Nephrology, Vol. 17, No. 4, 12.1985, p. 323-330.

Research output: Contribution to journalArticle

@article{f649bdd04ff544a29b1a8adcb5e15a02,
title = "Effect of levamisol on cellular and humoral immune reactivity and on recurrences in patients with bladder papilloma",
abstract = "Ten patients who had undergone repeated surgical interventions for bladder papilloma with successive recurrences within intervals of a few months, were given levamisol in weekly doses of 300 mg over a year, and were followed up for various cellular immune reactions, as well as for serum globulin and for acute-phase protein concentrations in the course of treatment. Levamisol was found to act primarily on cell-borne responsiveness. The recurrence-free intervals increased in the course of treatment. Four patients have remained free from recurrences since the start of treatment.",
author = "I. Romics and J. Horv{\'a}th and J. Feh{\'e}r and A. Csontai",
year = "1985",
month = "12",
doi = "10.1007/BF02083502",
language = "English",
volume = "17",
pages = "323--330",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Effect of levamisol on cellular and humoral immune reactivity and on recurrences in patients with bladder papilloma

AU - Romics, I.

AU - Horváth, J.

AU - Fehér, J.

AU - Csontai, A.

PY - 1985/12

Y1 - 1985/12

N2 - Ten patients who had undergone repeated surgical interventions for bladder papilloma with successive recurrences within intervals of a few months, were given levamisol in weekly doses of 300 mg over a year, and were followed up for various cellular immune reactions, as well as for serum globulin and for acute-phase protein concentrations in the course of treatment. Levamisol was found to act primarily on cell-borne responsiveness. The recurrence-free intervals increased in the course of treatment. Four patients have remained free from recurrences since the start of treatment.

AB - Ten patients who had undergone repeated surgical interventions for bladder papilloma with successive recurrences within intervals of a few months, were given levamisol in weekly doses of 300 mg over a year, and were followed up for various cellular immune reactions, as well as for serum globulin and for acute-phase protein concentrations in the course of treatment. Levamisol was found to act primarily on cell-borne responsiveness. The recurrence-free intervals increased in the course of treatment. Four patients have remained free from recurrences since the start of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0022350809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022350809&partnerID=8YFLogxK

U2 - 10.1007/BF02083502

DO - 10.1007/BF02083502

M3 - Article

C2 - 3835174

AN - SCOPUS:0022350809

VL - 17

SP - 323

EP - 330

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 4

ER -